Here is the design of a clinical trial:

Official Title: Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria: A Randomised Controlled Clinical Trial

Included conditions:
- Malaria

Study Armgroups:
- {'label': 'Paracetamol', 'type': 'EXPERIMENTAL', 'description': '\\>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.\n\n\\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine.', 'interventionNames': ['Drug: Paracetamol']}
- {'label': 'No Paracetamol', 'type': 'NO_INTERVENTION', 'description': 'No Paracetamol plus IV artesunate or oral artemether/lumefantrine.\n\nIf temperature \\>39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives.'}

Interventions:
- {'type': 'DRUG', 'name': 'Paracetamol', 'description': '\\>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.\n\n\\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine.', 'armGroupLabels': ['Paracetamol'], 'otherNames': ['acetaminophen']}

Primary Outcomes:
- {'measure': 'Effect of Paracetamol on kidney function', 'description': 'Change in creatinine concentration (umol/L) at 72 hours from enrolment in patients receiving regularly-dosed paracetamol compared to those not receiving regular paracetamol, stratified by the level of intravascular haemolysis (cell-free haemoglobin).', 'timeFrame': '72 hours'}

Please estimate the sample size based on the assumption: 
Significance level (α) = 0.05; Power (1-β) = 0.9; Log-transformed estimated mean 72 h creatinine in control group = 4.38 μmol/L (SD 0.36); Log-transformed estimated mean 72 h creatinine in treatment group = 4.275 μmol/L (SD 0.36); Correlation between baseline and 72 h creatinine = 0.59; Loss to follow-up rate = 10%.
Sample size
        Our sample size for ANCOVA was calculated using the Stata command sampsi, with Î±â=â0.05; 1âââÎ² (power)â=â0.9; log-transformed estimated mean 72 h creatinine in control groupâ=â4.38 Î¼mol/L (estimated SD 0.36); log-transformed estimated mean 72 h creatinine in treatment groupâ=â4.275Â Î¼mol/L (estimated SD 0.36); correlation between baseline and 72 h creatinine (data log-transformed)â=â0.59. The mean 72 h creatinine in the control group, the correlation between baseline and 72 h creatinine, and the standard deviation of the creatinine was estimated using existing data from prospectively enrolled patients with non-severe knowlesi malaria at a tertiary hospital in Sabah [9], with non-severe malaria patients used to more accurately reflect the patients at the district hospital sites. The mean 72 h creatinine in the treatment group was estimated using an estimated effect size of 10%, consistent with data from a pilot randomised trial of regularly dosed paracetamol, versus no paracetamol, in patients with severe and moderately severe falciparum malaria in Bangladeshi adults [29]. We estimated that this effect size would be similar in patients with knowlesi malaria of any severity, given the greater haemolysis that occurs in severe knowlesi malaria compared to severe falciparum malaria, and in non-severe knowlesi malaria compared to non-severe falciparum malaria [32].
        Using the above calculation, a minimum sample size of 324 will be required. Allowing for a loss to follow-up of 10% (primarily due to patients discharged from hospital <â72Â h), we will require a minimum of 360 patients enrolled in the study, 180 in each arm.